ArticleDiscover oncology2026
ATP2C2-PLA2R1 axis underlies lipid metabolism modulation and invasion in papillary thyroid carcinoma mediated by a VGIC signature.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivePapillary thyroid carcinoma (PTC) is the most common thyroid malignancy, with rising incidence globally. Current prognostic markers often lack precision for individualized management. This study develops a prognostic signature based on voltage-gated ion channel (VGIC) genes and explores its relationship with the tumor metabolic microenvironment in PTC.
methodsWe analyzed transcriptomic and clinical data from GEO and TCGA, focusing on VGIC genes identified via GeneCards. Prognostic VGICs were selected using univariate Cox regression, LASSO, and multivariate Cox analysis to construct a risk-score model. Model performance was assessed via ROC curves and nomograms. Kaplan-Meier analysis compared survival between high- and low-risk groups. We further evaluated differences in immune cell infiltration and metabolic microenvironment. Key differentially expressed genes (DEGs) underwent experimental validation.
resultsFrom integrated GEO and GeneCards data, we identified 172 VGIC-related DEGs. LASSO-Cox regression refined this set to six prognostic VGIC genes: PDLIM3, FGF7, ANO5, ATP2C2, PLAG1, and STMN2. High-risk patients exhibited significantly poorer overall survival. The high- and low-risk groups also showed distinct immune profiles and metabolic microenvironments. A nomogram incorporating patient age and risk score predicted 1-, 3-, and 5-year survival with strong accuracy. RT-qPCR confirmed differential expression of the six genes in PTC cell lines: PDLIM3, FGF7, ANO5, and ATP2C2 were downregulated in PTC versus normal thyroid cells. Among them, ATP2C2 emerged as a key regulator linked to lipid metabolism gene PLA2R1. Functional assays revealed that manipulating ATP2C2 levels modulated PLA2R1 expression.
conclusionSpecific VGIC gene signatures provide powerful prognostic biomarkers in PTC. Beyond improving prognosis, targeting these VGICs-especially ATP2C2-offers a novel approach to reshape the tumor metabolic microenvironment and inhibit PTC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.